Gene-expression profiling of HIV-1 infection and perinatal transmission in Botswana

Genes and Immunity

Volumn 7, Issue 4, 2006, Pages 298-309

  Montano, M ^a,c   Rarick, M ^a   Sebastiani, P ^b   Brinkmann, P ^a,c   Russell, M ^a   Navis, A ^a   Wester, C ^d   Thior, I ^c,d   Essex, M ^c,d  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d BOTSWANA HARVARD AIDS INSTITUTE PARTNERSHIP   (Botswana)

Author keywords

Botswana; HIV 1; Microarray; Transmission

Indexed keywords

INTERFERON; TOLL LIKE RECEPTOR; VIRUS RNA;

ADOLESCENT; ADULT; ARTICLE; BOTSWANA; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION PROFILING; GENE FUNCTION; GENE PROBE; GENETIC ASSOCIATION; GENETIC CODE; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; INFECTION RISK; INNATE IMMUNITY; MICROARRAY ANALYSIS; NONHUMAN; PERINATAL INFECTION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS; RNA PROCESSING; RNA SPLICING; RNA VIRUS; SARS CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; VALIDATION PROCESS; VERTICAL TRANSMISSION; VIRUS STRAIN; VIRUS TRANSMISSION;

ADOLESCENT; ADULT; BOTSWANA; CROSS-SECTIONAL STUDIES; DISEASE TRANSMISSION, VERTICAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFANT; INFANT, NEWBORN; INTERFERON TYPE II; MOTHERS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RNA PROCESSING, POST-TRANSCRIPTIONAL; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS; VIRAL LOAD;

HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES;

EID: 33745038718     PISSN: 14664879     EISSN: 14765470     Source Type: Journal    
DOI: 10.1038/sj.gene.6364297     Document Type: Article

References (105)

1. St Louis ME, Kamenga M, Brown C, Nelson AM, Manzila T, Batter V et al. Risk for perinatal HIV-1 transmission according to maternal immunologic, virologic, placental factors. JAMA 1993; 269: 2853-2859.
2. ECS. Maternal viral load, vertical transmission of HIV-1: An important factor but not the only one. The European Collaborative Study. AIDS 1999; 13: 1377-1385.
3. Ryder RW, Nsa W, Hassig SE, Behets F, Rayfield M, Ekungola B et al. Perinatal transmission of the human immunodeficiency virus type 1 to infants of seropositive women in Zaire. New Engl J Med 1989; 320: 1637-1642.
4. Ugen KE, Goedert JJ, Boyer J, Refaeli Y, Frank I, Williams WV et al. Vertical transmission of human immunodeficiency virus (HIV) infection. Reactivity of maternal sera with glycoprotein 120 and 41 peptides from HIV type 1. J Clin Invest 1992; 89: 1923-1930.
5. Halsey NA, Markham R, Wahren B, Boulos R, Rossi P, Wigzell H. Lack of association between maternal antibodies to V3 loop peptides and maternal-infant HIV-1 transmission. J Acquir Immune Defic Syndr 1992; 5: 153-157.
6. Eshleman SH, Guay LA, Mwatha A, Brown E, Musoke P, Mmiro F et al. Comparison of mother-to-child transmission rates in Ugandan women with subtype A versus D HIV-1 who received single-dose nevirapine prophylaxis: HIV Network For Prevention Trials 012. J Acquir Immune Defic Syndr 2005; 39: 593-597.
7. Ahmad N. The vertical transmission of human immunodeficiency virus type 1: Molecular and biological properties of the virus. Crit Rev Clin Lab Sci 2005; 42: 1-34.
8. Renjufi B, Gilbert P, Chaplin B, Msamanga G, Mwakagile D, Fawzi W et al. Preferential in-utero transmission of HIV-1 subtype C as compared to HIV-1 subtype A or D. AIDS 2004; 18: 1629-1636.
9. Salvatori F, Scarlatti G. HIV type 1 chemokine receptor usage in mother-to-child transmission. AIDS Res Hum Retroviruses 2001; 17: 925-935.
10. Mangano A, Gonzalez E, Dhanda R, Catano G, Bamshad M, Bock A et al. Concordance between the CC chemokine receptor 5 genetic determinants that alter risks of transmission and disease progression in children exposed perinatally to human immunodeficiency virus. J Infect Dis 2001; 183: 1574-1585.
11. Ometto L, Zanchetta M, Mainardi M, De Salvo GL, Garcia-Rodriguez MC, Gray L et al. Co-receptor usage of HIV-1 primary isolates, viral burden, and CCR5 genotype in mother-to-child HIV-1 transmission. AIDS 2000; 14: 1721-1729.
12. Johann-Liang R, Lee SE, Fernandez A, Cervia J, Noel GJ. Genotypic characterization of human immunodeficiency virus type 1 isolated from vertically infected children with antiretroviral therapy experience. Pediatr Infect Dis J 2000; 19: 363-364.
13. Welles SL, Pitt J, Colgrove R, McIntosh K, Chung PH, Colson A et al. HIV-1 genotypic zidovudine drug resistance and the risk of maternal-infant transmission in the women and infants transmission study. The Women and Infants Transmission Study Group. AIDS 2000; 14: 263-271.
14. Sato H, Shiino T, Kodaka N, Taniguchi K, Tomita Y, Kato K et al. Evolution and biological characterization of human immunodeficiency virus type 1 subtype E gp120 V3 sequences following horizontal and vertical virus transmission in a single family. J Virol 1999; 73: 3551-3559.
15. Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. New Engl J Med 1994; 331: 1173-1180.
16. Osmanov S, Pattou C, Walker N, Schwardlander B, Esparza J. Estimated global distribution and regional spread of HIV-1 genetic subtypes in the year 2000. J Acquir Immune Defic Syndr 2002; 29: 184-190.
17. Masupu K, Seipone K, Roels T, Kim S, Mmelesi M, Ekanem E et al., (eds) Botswana 2003 second generation HIV/AIDS surveillance: A technical report. Gaborone (Botswana): National AIDS Coordinating Agency, 2003. November.
18. Montano M, Russell M, Gilbert P, Thior I, Lockman S, Shapiro R et al. Comparative prediction of perinatal human immunodeficiency virus type 1 transmission, using multiple virus load markers. J Infect Dis 2003; 188: 406-413.
19. Mayaux MJ, Dussaix E, Isopet J, Rekacewicz C, Mandelbrot L, Ciraru-Vigneron N et al. Maternal virus load during pregnancy and mother-to-child transmission of human immunodeficiency virus type 1: The French perinatal cohort studies. SEROGEST Cohort Group. J Infect Dis 1997; 175: 172-175.
20. Cao Y, Krogstad P, Korber BT, Koup RA, Muldoon M, Macken C et al. Maternal HIV-1 viral load and vertical transmission of infection: The Ariel Project for the prevention of HIV transmission from mother to infant. Nat Med 1997; 3: 549-552.
21. Sperling RS, Shapiro DE, Coombs RW, Todd JA, Herman SA, McSherry GD et al. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1996; 335: 1621-1629.
22. Mofenson LM. Short-course zidovudine for prevention of perinatal infection. Lancet 1999; 353: 766-767.
23. Lambert G, Thea DM, Pliner V, Steketee RW, Abrams EJ, Matheson P et al. Effect of maternal CD4+ cell count, acquired immunodeficiency syndrome, and viral load on disease progression in infants with perinatally acquired human immunodeficiency virus type 1 infection. New York City Perinatal HIV Transmission Collaborative Study Group. J Pediatr 1997; 130: 890-897.
24. Burns DN, Landesman S, Wright DJ, Waters D, Mitchell RM, Rubinstein A et al. Influence of other maternal variables on the relationship between maternal virus load and mother-to-infant transmission of human immunodeficiency virus type 1. J Infect Dis 1997; 175: 1206-1210.
25. Fang G, Burger H, Grimson R, Tropper P, Nachman S, Mayers D et al. Maternal plasma human immunodeficiency virus type 1 RNA level: A determinant and projected threshold for mother-to-child transmission. Proc Natl Acad Sci USA 1995; 92: 12100-12104.
26. Dickover RE, Garratty EM, Herman SA, Sim MS, Plaeger S, Boyer PJ et al. Identification of levels of maternal HIV-1 RNA associated with risk of perinatal transmission. Effect of maternal zidovudine treatment on viral load. JAMA 1996; 275: 599-605.
27. Garcia PM, Kalish LA, Pitt J, Minkoff H, Quinn TC, Burchett SK et al. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group. N Engl J Med 1999; 341: 394-402.
28. Melvin AJ, Burchett SK, Watts DH, Hitti J, Hughes JP, McLellan CL et al. Effect of pregnancy and zidovudine therapy on viral load in HIV-1-infected women. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 14: 232-236.
29. Mock PA, Shaffer N, Bhadrakom C, Siriwasin W, Chotpitayasunondh T, Chearskul S et al. Maternal viral load and timing of mother-to-child HIV transmission, Bangkok, Thailand. Bangkok Collaborative Perinatal HIV Transmission Study Group. AIDS 1999; 13: 407-414.
30. Shaffer N, Roongpisuthipong A, Siriwasin W, Chotpitayasunondh T, Chearskul S, Young NL et al. Maternal virus load and perinatal human immunodeficiency virus type 1 subtype E transmission, Thailand. Bangkok Collaborative Perinatal HIV Transmission Study Group. J Infect Dis 1999; 179: 590-599.
31. O'Donovan D, Ariyoshi K, Milligan P, Ota M, Yamuah L, Sarge-Njie R et al. Maternal plasma viral RNA levels determine marked differences in mother-to-child transmission rates of HIV-1 and HIV-2 in The Gambia. MRC/ Gambia Government/University College London Medical School working group on mother-child transmission of HIV. AIDS 2000; 14: 441-448.
32. Katzenstein DA, Mbizvo M, Zijenah L, Gittens T, Munjoma M, Hill D et al. Serum level of maternal human immunodeficiency virus (HIV) RNA, infant mortality, and vertical transmission of HIV in Zimbabwe. J Infect Dis 1999; 179: 1382-1387.
33. Contopoulos-loannidis DG, Ioannidis JP. Maternal cell-free viremia in the natural history of perinatal HIV-1 transmission: A meta-analysis. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18: 126-135.
34. Shaffer N, Chuachoowong R, Mock PA, Bhadrakom C, Siriwasin W, Young NL et al. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: A randomised controlled trial. Bangkok Collaborative Perinatal HIV Transmission Study Group. Lancet 1999; 353: 773-780.
35. Matt C, Roger M. Genetic determinants of pediatric HIV-1 infection: vertical transmission and disease progression among children. Mot Med 2001; 7: 583-589.
36. John GC, Rousseau C, Dong T, Rowland-Jones S, Nduati R, Mbori-Ngacha D et al. Maternal SDF1 3′ A polymorphism is associated with increased perinatal human immunodeficiency virus type 1 transmission. J Virol 2000; 74: 5736-5739.
37. John GC, Bird T, Overbaugh J, Nduati R, Mbori-Ngacha D, Rostron T et al. CCR5 promoter polymorphisms in a Kenyan perinatal human immunodeficiency virus type 1 cohort: Association with increased 2-year maternal mortality. J Infect Dis 2001; 184: 89-92.
38. Kostrikis LG, Neumann AU, Thomson B, Korber BT, McHardy P, Karanicolas R et al. A polymorphism in the regulatory region of the CC-chemokine receptor 5 gene influences perinatal transmission of human immunodeficiency virus type 1 to African-American infants. J Virol 1999; 73: 10264-10271.
39. Kuhn L, Coutsoudis A, Moodley D, Mngqundaniso N, Trabattoni D, Shearer GM et al. Interferon-gamma and interleukin-10 production among HIV-1-infected and uninfected infants of HIV-1-infected mothers. Pediatr Res 2001; 50: 412-416.
40. Ockenhouse CF, Bernstein WB, Wang Z, Vahey MT. Functional genomic relationships in HIV-1 disease revealed by gene-expression profiling of primary human peripheral blood mononuclear cells. J Infect Dis 2005; 191: 2064-2074.
41. Li Q, Schacker T, Carlis J, Beilman G, Nguyen P, Haase AT. Functional genomic analysis of the response of HIV-1-infected lymphatic tissue to antiretroviral therapy. J Infect Dis 2004; 189: 572-582.
42. Hogan CM, Hammer SM. Host determinants in HIV infection and disease. Part 1: Cellular and humoral immune responses. Ann Intern Med 2001; 134: 761-776.
43. Hogan CM, Hammer SM. Host determinants in HIV infection and disease. Part 2: Genetic factors and implications for antiretroviral therapeutics. Ann Intern Med 2001; 134: 978-996.
44. Fauci AS. HIV and AIDS: 20 years of science. Nat Med 2003; 9: 839-843.
45. O'Brien SJ, Moore JP. The effect of genetic variation in chemokines and their receptors on HIV transmission and progression to AIDS. Immunol Rev 2000; 177: 99-111.
46. Carrington M, O'Brien SJ. The influence of HLA genotype on AIDS. Annu Rev Med 2003; 54: 535-551.
47. Dean M, Carrington M, Winkler C, Huttley GA, Smith MW, Allikmets R et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. [see comment] [erratum appears in Science 1996 Nov 15; 274(5290): 1069]. Science 1996; 273: 1856-1862.
48. Martin MP, Dean M, Smith MW, Winkler C, Gerrard B, Michael NL et al. Genetic acceleration of AIDS progression by a promoter variant of CCR5. Science 1998; 282: 1907-1911.
49. Dean M, Jacobson LP, McFarlane G, Margolick JB, Jenkins FJ, Howard OM et al. Reduced risk of AIDS lymphoma in individuals heterozygous for the CCR5-delta32 mutation. Cancer Res 1999; 59: 3561-3564.
50. Smith MW, Dean M, Carrington M, Winkler C, Huttley GA, Lomb DA et al. Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study. Science 1997; 277: 959-965.
51. Anzala AO, Ball TB, Rostron T, O'Brien SJ, Plummer FA, Rowland-Jones SL. CCR2-64I allele and genotype association with delayed AIDS progression in African women. University of Nairobi Collaboration for HIV Research. Lancet 1998; 351: 1632-1633.
52. An P, Nelson GW, Wang L, Donfield S, Goedert JJ, Phair J et al. Modulating influence on HIV/AIDS by interacting RANTES gene variants. Proc Natl Acad Sci USA 2002; 99: 10002-10007.
53. Winkler C, Modi W, Smith MW, Nelson GW, Wu X, Carrington M et al. Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. ALIVE Study, Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC) [see comment]. Science 1998; 279: 389-393.
54. Duggal P, An P, Beaty TH, Strathdee SA, Farzadegan H, Markham RB et al. Genetic influence of CXCR6 chemokine receptor alleles on PCP-mediated AIDS progression among African Americans. Genes Immun 2003; 4: 245-250.
55. Modi WS, Goedert JJ, Strathdee S, Buchbinder S, Detels R, Donfield S et al. MCP-1-MCP-3-Eotaxin gene cluster influences HIV-1 transmission. AIDS 2003; 17: 2357-2365.
56. Shin HD, Winkler C, Stephens JC, Bream J, Young H, Goedert JJ et al. Genetic restriction of HIV-1 pathogenesis to AIDS by promoter alleles of IL10. Proc Natl Acad Sci USA 2000; 97: 14467-14472.
57. An P, Vlahov D, Margolick JB, Phair J, O'Brien TR, Lautenberger J et al. A tumor necrosis factor-alpha-inducible promoter variant of interferon-gamma accelerates CD4+ T cell depletion in human immunodeficiency virus-1-infected individuals. J Infect Dis 2003; 188: 228-231.
58. Gao X, Nelson GW, Karacki P, Martin MP, Phair J, Kaslow R et al. Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS [see comment]. New Engl J Med 2001; 344: 1668-1675.
59. Carrington M, Nelson GW, Martin MP, Kissner T, Vlahov D, Goedert JJ et al. HLA and HIV-1: Heterozygote advantage and B*35-Cw*04 disadvantage [see comment]. Science 1999; 283: 1748-1752.
60. Tang J, Costello C, Keet IP, Rivers C, Leblanc S, Karita E et al. HLA class I homozygosity accelerates disease progression in human immunodeficiency virus type 1 infection. AIDS Res Hum Retroviruses 1999; 15: 317-324.
61. Martin MP, Gao X, Lee JH, Nelson GW, Detels R, Goedert JJ et al. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat Genet 2002; 31: 429-434.
62. An P, Bleiber G, Duggal P, Nelson G, May M, Mangeat B et al. APOBEC3G genetic variants and their influence on the progression to AIDS. J Virol 2004; 78: 11070-11076.
63. O'Brien SJ, Nelson GW. Human genes that limit AIDS. Nat Genet 2004; 36: 565-574.
64. Klings ES, Safaya S, Adewoye AH, Odhiambo A, Frampton G, Lenburg M et al. Differential gene expression in pulmonary artery endothelial cells exposed to sickle cell plasma. Physiol Genomics 2005; 21: 293-298.
65. Sebastiani P, Jeneralczuk J, Ramoni M. Design and Analysis of Screening Experiments with Microarrays. New York: Springer Verlag, 2005.
66. Sebastiani P, Ramoni M, Kohane I. Bayesian clustering of gene expression dynamics. In: Parmigiani G, Garrett ES, Irizarry R, Zeger S (eds). The Analysis of Gene Expression Data: Methods and Software. New York: Springer Verlag, 2003, pp 400-427.
67. Hosack DA, Dennis Jr G, Sherman BT, Lane HC, Lempicki RA. Identifying biological themes within lists of genes with EASE. Genome Biol 2003; 4: R70.
68. Montano M, Rarick M, Sebastiani P, Brinkmann P, Skefos J, Ericksen R. HIV-1 burden influences host response to coinfection with Neisseria gonorrhoeae in vitro. Int Immunol 2006; 18: 125-137.
69. Reghunathan R, Jayapal M, Hsu LY, Chng HH, Tai D, Leung BP et al. Expression profile of immune response genes in patients with severe acute respiratory syndrome. BMC Immunol 2005; 6: 2.
70. Montano M, Williamson C. The molecular virology of HIV-1. In: Essex M (ed). AIDS in Africa. New York: Kluwer Academic, 2002, pp 11-34.
71. Ziebuhr J. Molecular biology of severe acute respiratory syndrome coronavirus. Curr Opin Microbiol 2004; 7: 412-419.
72. Moynagh PN. TLR signalling and activation of IRFs: Revisiting old friends from the NF-kappaB pathway. Trends Immunol 2005; 26: 469-476.
73. Doyle S, Vaidya S, O'Connell R, Dadgostar H, Dempsey P, Wu T et al. IRF3 mediates a TLR3/TLR4-specific antiviral gene program. Immunity 2002; 17: 251-263.
74. Le Bon A, Tough DF. Links between innate and adaptive immunity via type I interferon. Curr Opin Immunol 2002; 14: 432-436.
75. Honda K, Yanai H, Takaoka A, Taniguchi T. Regulation of the type I IFN induction: A current view. Int Immunol 2005; 17: 1367-1378.
76. Beutler B, Hoebe K, Georgel P, Tabeta K, Du X. Genetic analysis of innate immunity: Identification and function of the TIR adapter proteins. Adv Exp Med Biol 2005; 560: 29-39.
77. Tough DF, Borrow P, Sprent J. Induction of bystander T cell proliferation by viruses and type I interferon in vivo. Science 1996; 272: 1947-1950.
78. Le Bon A, Etchart N, Rossmann C, Ashton M, Hou S, Gewert D et al. Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon. Nat Immunol 2003; 4: 1009-1015.
79. Ahonen CL, Doxsee CL, McGurran SM, Riter TR, Wade WF, Barth RJ et al. Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type I IFN. J Exp Med 2004; 199: 775-784.
80. Blander JM, Medzhitov R. Regulation of phagosome maturation by signals from toll-like receptors [see comment]. Science 2004; 304: 1014-1018.
81. Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira S et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8 [see comment]. Science 2004; 303: 1526-1529.
82. Bafica A, Scanga CA, Equils O, Sher A. The induction of Toll-like receptor tolerance enhances rather than suppresses HIV-1 gene expression in transgenic mice. J Leukocyte Biol 2004; 75: 460-466.
83. Equils O, Madak Z, Liu C, Michelsen KS, Bulut Y, Lu D. Rac1 and Toll-IL-1 receptor domain-containing adapter protein mediate Toll-like receptor 4 induction of HIV-long terminal repeat. J Immunol 2004; 172: 7642-7646.
84. Heggelund L, Damas JK, Yndestad A, Holm AM, Muller F, Lien E et al. Stimulation of toll-like receptor 2 in mononuclear cells from HIV-infected patients induces chemokine responses: Possible pathogenic consequences. Clin Exp Immunol 2004; 138: 116-121.
85. Taniguchi T, Ogasawara K, Takaoka A, Tanaka N. IRF family of transcription factors as regulators of host defense. Annu Rev Immunol 2001; 19: 623-655.
86. Leonard WJ, O'Shea JJ. Jaks and STATs: Biological implications. Ann Rev Immunol 1998; 16: 293-322.
87. Kohler JJ, Tuttle DL, Coberley CR, Sleasman JW, Goodenow MM. Human immunodeficiency virus type 1 (HIV-1) induces activation of multiple STATs in CD4+ cells of lymphocyte or monocyte/macrophage lineages. J Leukocyte Biol 2003; 73: 407-416.
88. Bovolenta C, Camorali L, Lorini AL, Ghezzi S, Vicenzi E, Lazzarin A et al. Constitutive activation of STATs upon in vivo human immunodeficiency virus infection. Blood 1999; 94: 4202-4209.
89. Battistini A, Marsili G, Sgarbanti M, Ensoli B, Hiscott J. IRF regulation of HIV-1 long terminal repeat activity. J Interferon Cytokine Res 2002; 22: 27-37.
90. Marsili G, Borsetti A, Sgarbanti M, Remoli AL, Ridolfi B, Stellacci E et al. On the role of interferon regulatory factors in HIV-1 replication. Ann NY Acad Sci 2003; 1010: 29-42.
91. Sgarbanti M, Borsetti A, Moscufo N, Bellocchi MC, Ridolfi B, Nappi F et al. Modulation of human immunodeficiency virus 1 replication by interferon regulatory factors. J Exp Med 2002; 195: 1359-1370.
92. Izmailova E, Bertley FM, Huang Q, Makori N, Miller CJ, Young RA et al. HIV-1 Tat reprograms immature dendritic cells to express chemoattractants for activated T cells and macrophages. Nat Med 2003; 9: 191-197.
93. Bosinger SE, Hosiawa KA, Cameron MJ, Persad D, Ran L, Xu L et al. Gene expression profiling of host response in models of acute HIV infection. J Immunol 2004; 173: 6858-6863.
94. Samuel CE. Antiviral actions of interferons. Clin Microbiol Rev 2001; 14: 778-809.
95. Lee BN, Hammill H, Popek EJ, Cron S, Kozinetz C, Paul M et al. Production of interferons and beta-chemokines by placental trophoblasts of HIV-1-infected women. Infect Dis Obstet Gynecol 2001; 9: 95-104.
96. Sheehy AM, Gaddis NC, Choi JD, Malim MH. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein [see comment]. Nature 2002; 418: 646-650.
97. Koulinska IN, Chaplin B, Mwakagile D, Essex M, Renjifo B. Hypermutation of HIV type 1 genomes isolated from infants soon after vertical infection. AIDS Res Hum Retroviruses 2003; 19: 1115-1123.
98. Bagasra O, Prilliman KR. RNA interference: The molecular immune system. J Mol Histol 2004; 35: 545-553.
99. Ropers D, Ayadi L, Gattoni R, Jacquenet S, Damier L, Branlant C et al. Differential effects of the SR proteins 9G8, SC35, ASF/SF2, and SRp40 on the utilization of the A1 to A5 splicing sites of HIV-1 RNA. J Biol Chem 2004; 279: 29963-29973.
100. Maldarelli F, Xiang C, Chamoun G, Zeichner SL. The expression of the essential nuclear splicing factor SC35 is altered by human immunodeficiency virus infection. Virus Res 1998; 53: 39-51.
101. Ryo A, Suzuki Y, Arai M, Kondoh N, Wakatsuki T, Hada A et al. Identification and characterization of differentially expressed mRNAs in HIV type 1-infected human T cells. AIDS Res Hum Retroviruses 2000; 16: 995-1005.
102. Chun TW, Justement JS, Lempicki RA, Yang J, Dennis Jr G, Hallahan CW et al. Gene expression and viral prodution in latently infected, resting CD4+ T cells in viremic versus aviremic HIV-infected individuals. Proc Natl Acad Sci USA 2003; 100: 1908-1913.
103. Zhang Z, Krainer AR. Involvement of SR proteins in mRNA surveillance. Mol Cell 2004; 16: 597-607.
104. Sebastiani P, Ramoni MF, Nolan V, Baldwin CT, Steinberg MH. Genetic dissection and prognostic modeling of overt stroke in sickle cell anemia. Nat Genet 2005; 37: 435-440.
105. Rarick M, McPheeters C, Bright S, Navis A, Skefos J, Sebastiani P et al. Evidence for cross-regulated cytokine response in human PBMCs exposed to whole gonococcal bacteria, in vitro. Microb Pathog 2005, in press.